Skip to main content

Table 1 Demographics and baseline characteristics for patients treated in the trial

From: A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Baseline characteristic MK-2206 dosing cohort
45 mg QOD 60 mg QOD 135 mg QW 200 mg QW All cohorts
(n = 3) (n = 11) (n = 11) (n = 6) (N = 31)
Gender, n (%)
 Male 0 (0.0) 1 (9.1) 0 (0.0) 2 (33.3) 3 (9.7)
 Female 3 (100.0) 10 (90.9) 11 (100.0) 4 (66.7) 28 (90.3)
Age (years)
 Median 44 55.5 49 48.5 51.5
 Range 36 to 52 44 to 67 37 to 61 38 to 59 36 to 67
Cancer type, n (%)
 Breast 3 (100.0) 10 (90.9) 11 (84.6) 3 (50.0) 27 (87.1)
 Gastric 0 (0.0) 1 (9.1) 0 (0.0) 3 (50.0) 4 (12.9)
Cancer stage, n (%)
 Intravenous 3 (100.0) 11 (100.0) 11 (100.0) 6 (100.0) 31 (100.0)
ECOG status, n (%)
 0 3 (75.0) 7 (63.6) 10 (91.0) 4 (66.7) 24 (77.4)
 1 0 (0.0) 4 (36.4) 1 (9.0) 2 (33.3) 7 (22.6)
Number of prior therapies, n (%)
 1 or 2 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 2 (6.5)
 ≥3 3 (100.0) 11 (100.0) 11 (100.0) 4 (66.7) 29 (93.5)
  1. ECOG, Eastern Cooperative Oncology Group; QOD, every other day; QW, every week.